Kothari Aditi, Aparece John Paul, Del Toro Mijares Raul
Division of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Curr Cardiol Rep. 2025 Apr 7;27(1):80. doi: 10.1007/s11886-025-02223-w.
The increasing prevalence of attention deficit hyperactivity disorder (ADHD) makes it important to study the cardiovascular implications of this disease and the drugs used to treat it. As more patients are diagnosed with ADHD across the world and these medications are prescribed more, it is imperative to understand the cardiovascular risk profile associated with these medications. This narrative review will highlight the importance of considering cardiovascular risk factors inherent to ADHD and the medications currently used to treat it.
Chronic sympathetic activation as caused by ADHD therapies has numerous effects on the cardiovascular system including an increase in blood pressure and heart rate. These changes could potentially lead to heart failure, arrythmias or even sudden cardiac death. While a few studies that have shown no correlation between ADHD medications and cardiovascular effects, current guidelines recommend a thorough assessment prior to initiating treatment and periodic monitoring during treatment.
注意缺陷多动障碍（ADHD）的患病率不断上升，因此研究该疾病及其治疗药物对心血管系统的影响具有重要意义。随着全球越来越多的患者被诊断为ADHD且这些药物的处方量增加，了解与这些药物相关的心血管风险状况势在必行。本叙述性综述将强调考虑ADHD固有的心血管危险因素以及目前用于治疗该疾病的药物的重要性。
ADHD治疗引起的慢性交感神经激活对心血管系统有诸多影响，包括血压和心率升高。这些变化可能会导致心力衰竭、心律失常甚至心源性猝死。虽然一些研究表明ADHD药物与心血管效应之间没有关联，但目前的指南建议在开始治疗前进行全面评估，并在治疗期间定期监测。
